-
Merck KGaA’s Tepmetko Launches in China, Expanding Access to MET Inhibitor for Lung Cancer Patients
•
Merck KGaA (NYSE: MRK), a leading German science and technology company, has announced the commercial launch of its targeted lung cancer therapy, Tepmetko (tepotinib), in China. This marks a significant milestone as multiple hospitals across the country have begun writing the first prescriptions for this MET inhibitor. Tepmetko, which has…
-
Chia Tai Tianqing and Fudan University Shanghai Cancer Center Join Forces for Innovative Drug Development
•
Chia Tai Tianqing, a China-based pharmaceutical company, has entered into a strategic partnership with Fudan University Shanghai Cancer Center to intensify their collaboration on clinical trials for innovative drugs. The agreement leverages Chia Tai Tianqing’s comprehensive industrial chain strength in scientific and technological innovation and the Shanghai Cancer Center’s leading…
-
Takeda Secures Rights to Protagonist Therapeutics’ Rusfertide in Landmark Deal
•
Takeda Pharmaceuticals Company Limited (TYO: 4502) has announced a significant expansion of its hematology portfolio with the acquisition of partial commercial rights to Protagonist Therapeutics Inc.’s investigational drug rusfertide in the U.S., and full rights outside the country. The agreement entails an upfront payment of USD 300 million to the…
-
Shanghai Junshi Biosciences’ Toripalimab Aims for Singapore Approval in Nasopharyngeal Carcinoma
•
Shanghai Junshi Biosciences Co., Ltd (HKG: 1877; SHA: 688180), a leading biopharmaceutical company based in China, has submitted market approval applications in Singapore for its programmed death-1 (PD-1) inhibitor, Loqtorzi (toripalimab). The drug is proposed for use as a first-line treatment for metastatic or recurrent locally advanced nasopharyngeal carcinoma (NPC)…
-
Novo Nordisk Delivers Strong 2023 Results with Record-Breaking Sales
•
Novo Nordisk A/S (NYSE: NVO), a Denmark-based pharmaceutical company, has announced its financial results for the fourth quarter and the full year of 2023, showcasing a remarkable performance. The company’s revenues reached DKK 232.3 billion (USD 33.75 billion), reflecting a 36% year-on-year growth in constant currency terms. The standout product…
-
Sanofi Reports Full-Year Revenue Growth Driven by Dupixent and Vaccines, Eyes Biopharma Focus
•
Sanofi (NASDAQ: SNY), a leading French pharmaceutical company, has released its financial report for the fourth quarter and full year of 2023. The company’s global revenues for the 12-month period reached EUR 43.07 billion (USD 47 billion), marking a 5.3% increase year-on-year in constant currency terms. Key drivers of this…
-
Takeda Reports Flat 9-Month Revenue Growth Amid Pipeline Optimization Efforts
•
Takeda (TYO: 4502), a leading Japanese pharmaceutical company, has released its financial results for the 9-month period ended December 31, 2023, reporting a revenue of JPY 3.2 trillion (USD 21.9 billion) with a 0.0% growth at constant exchange rates (CER). The company’s performance was impacted by declines in oncology, neuroscience,…
-
Merck Q4 Sales Grow 6% YOY, Driven by Pharmaceutical Segment and HPV Vaccine Demand
•
Merck, Sharp & Dohme (MSD; NYSE: MRK), a leading US pharmaceutical company, has released its financial report for the fourth quarter and full year of 2023. In Q4, MSD generated USD 14.6 billion in sales, marking a 6% year-on-year increase, with growth expanding to 13% when excluding the impacts from…
